Rituximab: clinical development and future directions

被引:24
作者
Cheson, BD [1 ]
机构
[1] NCI, Bethesda, MD 20892 USA
关键词
antibody; CD20; CLL lymphoma; monoclonal; rituximab;
D O I
10.1517/14712598.2.1.97
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The availability of effective monoclonal antibodies (mAbs) has revolutionised the management of patients with B-cell malignancies. The most widely studied of these agents is rituximab (Rituxan(TM), IDEC Pharmaceuticals, San Diego, CA), a chimeric anti-CD20 antibody. Using the standard 4-weekly administration schedule, rituximab induces responses in almost half of patients with relapsed follicular/low-grade (F/LG) non-Hodgkin's lymphoma (NHL) with complete remissions in 6%. Lower response rates (RRs) have been noted in chronic lymphocytic leukaemia (CLL) using the standard dose and schedule. The drug has been well tolerated in most patients with common adverse events including mild to moderate fevers and chills and rare occurrences of a serious syndrome related to cytokine release and rapid tumour clearance. This antibody is also active against aggressive NHL, mantle cell NHL, post-transplant lymphoproliferative disorder (PTLD), lymphoplasmacytic NHL and hairy cell leukaemia and is also being evaluated in autoimmune disorders. Combinations of rituximab with chemotherapy regimens such as CHOP (cyclophosphamide, adriamycin, vincristine, predinisone) may alter the therapeutic paradigm for these diseases. The future promise of this antibody is a foundation on which to develop new strategies to increase the cure of patients with lymphoid malignancies.
引用
收藏
页码:97 / 110
页数:14
相关论文
共 108 条
[1]   Primary cutaneous large B-cell lymphoma of the legs - A distinct clinical pathologic entity treated with CD20 monoclonal antibody (Rituximab) [J].
Aboulafia, DM .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (03) :237-240
[2]  
Alas S, 2001, CANCER RES, V61, P5137
[3]  
Alas S, 2001, CLIN CANCER RES, V7, P709
[4]  
Ansell SM, 1999, BLOOD, V94, p86A
[5]  
Ansell SM, 2000, BLOOD, V96, p577A
[6]   Rituximab in the treatment of refractory follicular lymphoma -: Six doses are better than four [J].
Avilés, A ;
León, MI ;
Díaz-Maqueo, JC ;
García, EL ;
Cleto, S ;
Neri, N .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (02) :313-316
[7]   Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].
Berinstein, NL ;
Grillo-Lopez, AJ ;
White, CA ;
Bence-Bruckler, I ;
Maloney, D ;
Czuczman, M ;
Green, D ;
Rosenberg, J ;
McLaughlin, P ;
Shen, D .
ANNALS OF ONCOLOGY, 1998, 9 (09) :995-1001
[8]   Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma [J].
Bertolini, F ;
Fusetti, L ;
Mancuso, P ;
Gobbi, A ;
Corsini, C ;
Ferrucci, PF ;
Martinelli, G ;
Pruneri, G .
BLOOD, 2000, 96 (01) :282-287
[9]  
Buckstein RJ, 1999, BLOOD, V94, p355B
[10]  
Byrd JC, 1998, BLOOD, V92, p106A